CSPCY (CSPC Pharmaceutical Group) Interest Expense : $-6 Mil (TTM As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is CSPC Pharmaceutical Group Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. CSPC Pharmaceutical Group's interest expense for the three months ended in Jun. 2024 was $ -2 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2024 was $-6 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. CSPC Pharmaceutical Group's Operating Income for the three months ended in Jun. 2024 was $ 227 Mil. CSPC Pharmaceutical Group's Interest Expense for the three months ended in Jun. 2024 was $ -2 Mil. CSPC Pharmaceutical Group's Interest Coverage for the quarter that ended in Jun. 2024 was 103.64. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

CSPC Pharmaceutical Group Interest Expense Historical Data

The historical data trend for CSPC Pharmaceutical Group's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSPC Pharmaceutical Group Interest Expense Chart

CSPC Pharmaceutical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-4.62

-1.87

-1.20

-3.57

-3.63

CSPC Pharmaceutical Group Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Interest Expense	Get a 7-Day Free Trial															-0.84	-1.26	-0.85	-2.19	-1.60

CSPC Pharmaceutical Group Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6 Mil.

CSPC Pharmaceutical Group (OTCPK:CSPCY) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

CSPC Pharmaceutical Group's Interest Expense for the three months ended in Jun. 2024 was $-2 Mil. Its Operating Income for the three months ended in Jun. 2024 was $227 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2024 was $9 Mil.

CSPC Pharmaceutical Group's Interest Coverage for the quarter that ended in Jun. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Jun. 2024 )	/	Interest Expense (Q: Jun. 2024 )
	=	-1	*	226.773	/	-2.188
	=	103.64

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. CSPC Pharmaceutical Group Ltd has enough cash to cover all of its debt. Its financial situation is stable.

CSPC Pharmaceutical Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CSPC Pharmaceutical Group Ltd (OTCPK:CSPCY) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

CHJTF:USA 01093:Hong Kong CVG:Germany

Address

No. 226 Huanghe Street, Hebei Province, Shijiazhuang, CHN, 050035

Website

https://www.cspc.com.hk

CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C, antibiotics, and a caffeine series.

CSPC Pharmaceutical Group Headlines

From GuruFocus

Value Partners Classic Fund Comments on CSPC Pharmaceutical

By Vera Yuan Vera Yuan • 07-29-2014